Skip to main content
Premium Trial:

Request an Annual Quote

Personalis Prices $150M Public Stock Offering

NEW YORK – Personalis said Wednesday that it has priced a public offering of 3,950,000 shares of its common stock at $38 per share.

The Menlo Park, California-based firm expects gross proceeds from the offering to be about $150 million. It also is granting underwriters a 30-day option to purchase up to an additional 592,500 shares under the same terms and conditions.

Morgan Stanley, BofA Securities, Citigroup and Cowen are acting as joint book-running managers. BTIG is acting as co-manager.

Personalis, which has commercialized a suite of next-generation sequencing services for population genomics, cancer research, and diagnostics, said it would use proceeds from the offering for working capital and general corporate purposes.

In Wednesday morning trade on the Nasdaq, shares of Personalis were down around 10 percent at $38.43.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.